

AGENUS INC  
Form 8-K  
January 21, 2014

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

January 21, 2014  
Date of Report (Date of earliest event reported)

---

**AGENUS INC.**  
(Exact name of registrant as specified in its charter)

---

---

|                              |                  |                     |
|------------------------------|------------------|---------------------|
| <b>DELAWARE</b>              | <b>000-29089</b> | <b>06-1562417</b>   |
| (State or other jurisdiction | (Commission      | (IRS Employer       |
| of incorporation)            | File Number)     | Identification No.) |

**3 Forbes Road**

**Lexington, MA**

**02421**

(Address of principal executive offices) (Zip

**781-674-4400**

(Registrant's telephone number, including area code)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other events**

Agenus Inc. announced today that Phase 2 results of Prophage G-200 vaccine in recurrent patients with glioblastoma multiforme (GBM) were hailed as ‘exciting’ and a ‘very promising therapy’ in an editorial published in *Neuro-Oncology*, the leading journal of the Society of Neuro-Oncology. The results of Agenus’ Prophage vaccine Phase 2 study, published last month in *Neuro-Oncology*, demonstrated that more than 90% of the patients treated with the vaccine candidate were alive at six months. The median overall survival in these patients was approximately 11 months.

The full text of the press release issued in connection with the announcement is being filed as Exhibit 99.1 to this current report on Form 8-K.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

The following exhibit is filed herewith:

99.1 Press Release dated January 21, 2014

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**AGENUS INC.**

Date:     By: /s/ Garo H. Armen  
January  
21, 2014

Garo H. Armen  
Chief Executive Officer

---

EXHIBIT INDEX

| <u>Exhibit No.</u> | <u>Description of Exhibit</u>        |
|--------------------|--------------------------------------|
| 99.1               | Press Release dated January 21, 2014 |